D.E. Shaw & Co
TENX icon

D.E. Shaw & Co’s Tenax Therapeutics TENX Stock Holding History

D.E. Shaw & Co’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2
Closed -$246K – 4004
2014
Q4 		$246K Hold
2
– – ﹤0.01% 3723
2014
Q3 		$204K Sell
2
-2
-50% -$257K ﹤0.01% 3882
2014
Q2 		$511K Buy
+4
New +$617K ﹤0.01% 3515

Other funds holding TENX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's TENX Position: Q1 2015 in Review

D.E. Shaw & Co sold out of Tenax Therapeutics (TENX) in Q1 2015, closing a stake of 2 shares — an estimated $246K sold.

D.E. Shaw & Co first reported a position in TENX in Q2 2014 and held it in 3 quarters. The position peaked at $511K in Q2 2014. 16 funds tracked by Wall St. Rank hold TENX as of Q1 2015.

  • D.E. Shaw & Co reported no remaining Tenax Therapeutics position as of Q1 2015 after selling out during the quarter.
  • D.E. Shaw & Co sold 2 Tenax Therapeutics shares in Q1 2015, an estimated $246K.
  • D.E. Shaw & Co first reported a position in Tenax Therapeutics in Q2 2014 and held it in 3 quarters.
  • D.E. Shaw & Co's Tenax Therapeutics position peaked at $511K in Q2 2014.
  • 16 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2015.

Based on D.E. Shaw & Co's 13F filing for Q1 2015, filed 15 May 2015.